Chembio Diagnostics, Inc. Logo

Chembio Diagnostics, Inc.

CEMI

(0.8)
Stock Price

0,46 USD

-37.2% ROA

-89.47% ROE

-0.47x PER

Market Cap.

16.710.285,00 USD

140.93% DER

0% Yield

-48.18% NPM

Chembio Diagnostics, Inc. Stock Analysis

Chembio Diagnostics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Chembio Diagnostics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.62x), the stock offers substantial upside potential at a bargain price.

2 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-121.55%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-39.81%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 DER

The company has a high debt to equity ratio (141%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Chembio Diagnostics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Chembio Diagnostics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Chembio Diagnostics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Chembio Diagnostics, Inc. Revenue
Year Revenue Growth
2000 1
2001 0 0%
2002 0 0%
2003 0 0%
2004 3.305.932 100%
2005 3.940.730 16.11%
2006 6.502.480 39.4%
2007 9.230.948 29.56%
2008 11.049.571 16.46%
2009 13.834.248 20.13%
2010 16.704.703 17.18%
2011 19.388.036 13.84%
2012 25.610.595 24.3%
2013 29.549.609 13.33%
2014 27.645.284 -6.89%
2015 24.255.485 -13.98%
2016 17.868.841 -35.74%
2017 24.015.427 25.59%
2018 33.409.251 28.12%
2019 34.464.032 3.06%
2020 30.451.273 -13.18%
2021 36.926.726 17.54%
2022 36.646.844 -0.76%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Chembio Diagnostics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 1.433.403 100%
2005 1.364.898 -5.02%
2006 1.401.472 2.61%
2007 1.906.653 26.5%
2008 2.605.343 26.82%
2009 2.883.696 9.65%
2010 2.586.308 -11.5%
2011 4.878.119 46.98%
2012 4.486.302 -8.73%
2013 5.834.249 23.1%
2014 4.832.537 -20.73%
2015 6.377.839 24.23%
2016 8.427.554 24.32%
2017 8.555.381 1.49%
2018 8.526.256 -0.34%
2019 8.538.416 0.14%
2020 9.508.494 10.2%
2021 12.487.424 23.86%
2022 6.002.732 -108.03%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Chembio Diagnostics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 44.284 100%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 3.549.392 100%
2013 4.479.814 20.77%
2014 5.725.746 21.76%
2015 6.148.137 6.87%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Chembio Diagnostics, Inc. EBITDA
Year EBITDA Growth
2000 -132.513
2001 56.673 333.82%
2002 -46.649 221.49%
2003 -11.624 -301.32%
2004 -3.180.300 99.63%
2005 -3.199.479 0.6%
2006 -4.329.188 26.1%
2007 -2.713.667 -59.53%
2008 -1.690.877 -60.49%
2009 688.697 345.52%
2010 2.861.560 75.93%
2011 1.532.013 -86.78%
2012 1.452.102 -5.5%
2013 1.625.927 10.69%
2014 -810.824 300.53%
2015 -2.183.886 62.87%
2016 -6.407.001 65.91%
2017 -5.180.157 -23.68%
2018 -7.307.378 29.11%
2019 -11.885.660 38.52%
2020 -19.253.359 38.27%
2021 -21.074.409 8.64%
2022 -10.109.916 -108.45%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Chembio Diagnostics, Inc. Gross Profit
Year Gross Profit Growth
2000 1
2001 0 0%
2002 0 0%
2003 0 0%
2004 820.339 100%
2005 1.332.146 38.42%
2006 2.016.568 33.94%
2007 3.862.303 47.79%
2008 3.851.721 -0.27%
2009 5.860.405 34.28%
2010 8.100.699 27.66%
2011 9.390.303 13.73%
2012 10.789.991 12.97%
2013 12.300.159 12.28%
2014 10.814.023 -13.74%
2015 10.486.827 -3.12%
2016 8.451.336 -24.08%
2017 11.094.270 23.82%
2018 11.982.008 7.41%
2019 12.069.715 0.73%
2020 6.576.786 -83.52%
2021 2.430.924 -170.55%
2022 14.212.004 82.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Chembio Diagnostics, Inc. Net Profit
Year Net Profit Growth
2000 -128.864
2001 -72.815 -76.97%
2002 -47.651 -52.81%
2003 1.390 3528.13%
2004 -3.098.891 100.04%
2005 -3.252.000 4.71%
2006 -4.995.020 34.9%
2007 -2.626.892 -90.15%
2008 -1.948.770 -34.8%
2009 309.060 730.55%
2010 2.513.344 87.7%
2011 6.208.791 59.52%
2012 941.281 -559.61%
2013 530.818 -77.33%
2014 -1.137.203 146.68%
2015 -2.397.042 52.56%
2016 -13.347.047 82.04%
2017 -6.371.760 -109.47%
2018 -7.865.649 18.99%
2019 -13.675.129 42.48%
2020 -25.521.328 46.42%
2021 -33.903.529 24.72%
2022 -3.420.464 -891.2%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Chembio Diagnostics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 -115
2001 -35 -228.57%
2002 -6 -600%
2003 0 0%
2004 -4 100%
2005 -3 -33.33%
2006 -4 0%
2007 -1 -200%
2008 0 0%
2009 0 0%
2010 0 0%
2011 1 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 -1 100%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2020 -1 100%
2021 -1 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Chembio Diagnostics, Inc. Free Cashflow
Year Free Cashflow Growth
2000 -93.493
2001 -3.995 -2240.25%
2002 -26.026 84.65%
2003 -103.269 74.8%
2004 -2.708.359 96.19%
2005 -4.354.101 37.8%
2006 -4.577.436 4.88%
2007 -1.756.221 -160.64%
2008 -1.591.689 -10.34%
2009 -138.811 -1046.66%
2010 834.558 116.63%
2011 1.541.728 45.87%
2012 -111.358 1484.48%
2013 1.392.005 108%
2014 -5.272.900 126.4%
2015 762.393 791.62%
2016 -6.823.440 111.17%
2017 -6.061.469 -12.57%
2018 -13.256.235 54.27%
2019 -12.855.052 -3.12%
2020 -23.054.100 44.24%
2021 -32.743.399 29.59%
2022 -2.802.608 -1068.32%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Chembio Diagnostics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2000 -93.493
2001 -3.995 -2240.25%
2002 -26.026 84.65%
2003 -103.269 74.8%
2004 -2.647.807 96.1%
2005 -4.005.360 33.89%
2006 -4.202.923 4.7%
2007 -1.345.796 -212.3%
2008 -1.194.227 -12.69%
2009 251.927 574.04%
2010 1.016.850 75.22%
2011 2.268.408 55.17%
2012 761.084 -198.05%
2013 2.277.614 66.58%
2014 -3.820.299 159.62%
2015 1.792.978 313.07%
2016 -6.704.734 126.74%
2017 -5.034.515 -33.18%
2018 -11.789.043 57.29%
2019 -9.055.506 -30.19%
2020 -18.887.238 52.05%
2021 -30.885.716 38.85%
2022 -2.832.037 -990.58%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Chembio Diagnostics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 60.552 100%
2005 348.741 82.64%
2006 374.513 6.88%
2007 410.425 8.75%
2008 397.462 -3.26%
2009 390.738 -1.72%
2010 182.292 -114.35%
2011 726.680 74.91%
2012 872.442 16.71%
2013 885.609 1.49%
2014 1.452.601 39.03%
2015 1.030.585 -40.95%
2016 118.706 -768.18%
2017 1.026.954 88.44%
2018 1.467.192 30.01%
2019 3.799.546 61.39%
2020 4.166.862 8.82%
2021 1.857.683 -124.3%
2022 -29.429 6412.42%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Chembio Diagnostics, Inc. Equity
Year Equity Growth
2000 6.126
2001 -59.898 110.23%
2002 -106.169 43.58%
2003 -1.510 -6931.06%
2004 -2.950.994 99.95%
2005 1.052.703 380.33%
2006 -939.807 212.01%
2007 4.262.826 122.05%
2008 2.577.332 -65.4%
2009 3.087.914 16.53%
2010 5.808.944 46.84%
2011 12.494.634 53.51%
2012 13.874.520 9.95%
2013 20.177.102 31.24%
2014 19.724.162 -2.3%
2015 17.661.506 -11.68%
2016 17.169.586 -2.87%
2017 13.079.196 -31.27%
2018 33.267.858 60.69%
2019 24.035.253 -38.41%
2020 27.776.409 13.47%
2021 34.264.900 18.94%
2022 17.798.357 -92.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Chembio Diagnostics, Inc. Assets
Year Assets Growth
2000 7.497
2001 1.745 -329.63%
2002 4.012 56.51%
2003 0 0%
2004 1.426.449 100%
2005 3.016.406 52.71%
2006 7.906.577 61.85%
2007 6.584.997 -20.07%
2008 5.914.941 -11.33%
2009 6.315.250 6.34%
2010 9.086.174 30.5%
2011 15.485.744 41.33%
2012 17.335.150 10.67%
2013 24.486.592 29.21%
2014 25.010.192 2.09%
2015 20.816.344 -20.15%
2016 20.575.236 -1.17%
2017 16.616.021 -23.83%
2018 40.274.290 58.74%
2019 55.728.964 27.73%
2020 64.892.014 14.12%
2021 73.252.195 11.41%
2022 62.611.405 -16.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Chembio Diagnostics, Inc. Liabilities
Year Liabilities Growth
2000 1.371
2001 61.643 97.78%
2002 110.181 44.05%
2003 1.510 -7196.75%
2004 4.377.443 99.97%
2005 1.963.703 -122.92%
2006 8.846.384 77.8%
2007 2.322.171 -280.95%
2008 3.337.609 30.42%
2009 3.227.336 -3.42%
2010 3.277.230 1.52%
2011 2.991.110 -9.57%
2012 3.460.630 13.57%
2013 4.309.490 19.7%
2014 5.286.030 18.47%
2015 3.154.838 -67.55%
2016 3.405.650 7.36%
2017 3.536.825 3.71%
2018 7.006.432 49.52%
2019 31.693.711 77.89%
2020 37.115.605 14.61%
2021 38.987.295 4.8%
2022 44.813.048 13%

Chembio Diagnostics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.99
Net Income per Share
-0.96
Price to Earning Ratio
-0.47x
Price To Sales Ratio
0.35x
POCF Ratio
-0.87
PFCF Ratio
-1.18
Price to Book Ratio
0.62
EV to Sales
0.49
EV Over EBITDA
-1.62
EV to Operating CashFlow
-1.86
EV to FreeCashFlow
-1.67
Earnings Yield
-2.11
FreeCashFlow Yield
-0.85
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
3.97
Graham NetNet
-0.36

Income Statement Metrics

Net Income per Share
-0.96
Income Quality
0.55
ROE
-0.89
Return On Assets
-0.37
Return On Capital Employed
-0.88
Net Income per EBT
1
EBT Per Ebit
1.14
Ebit per Revenue
-0.42
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.15
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.2
Operating Profit Margin
-0.42
Pretax Profit Margin
-0.48
Net Profit Margin
-0.48

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.52
Free CashFlow per Share
-0.58
Capex to Operating CashFlow
0.11
Capex to Revenue
-0.03
Capex to Depreciation
-0.57
Return on Invested Capital
-0.48
Return on Tangible Assets
-0.37
Days Sales Outstanding
141.37
Days Payables Outstanding
31.63
Days of Inventory on Hand
73
Receivables Turnover
2.58
Payables Turnover
11.54
Inventory Turnover
5
Capex per Share
-0.06

Balance Sheet

Cash per Share
0,75
Book Value per Share
0,73
Tangible Book Value per Share
0.73
Shareholders Equity per Share
0.73
Interest Debt per Share
1.05
Debt to Equity
1.41
Debt to Assets
0.4
Net Debt to EBITDA
-0.47
Current Ratio
1.23
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
1.41
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,02 Bil.
Average Payables
0,01 Bil.
Average Inventory
10317932
Debt to Market Cap
1.5

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Chembio Diagnostics, Inc. Dividends
Year Dividends Growth

Chembio Diagnostics, Inc. Profile

About Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

CEO
Mr. Richard L. Eberly
Employee
188
Address
555 Wireless Boulevard
Hauppauge, 11788

Chembio Diagnostics, Inc. Executives & BODs

Chembio Diagnostics, Inc. Executives & BODs
# Name Age
1 Dr. Konstantin Lyashchenko
Research Director of Chembio Diagnostic Systems Inc
70
2 Mr. Lawrence J. Steenvoorden CPA
Executive Vice President, Chief Financial Officer & Sec.
70
3 Mr. Richard L. Eberly
Pres, Chief Executive Officer & Director
70
4 Mr. Javan Esfandiari
Executive Vice President and Chief Scientific & Technology Officer
70
5 Mr. Paul J. Angelico
Executive Vice President & Chief Operating Officer
70
6 Mr. Charles Caso
Senior Vice President of Global Commercial Operations
70
7 Ms. Stella Rivera
Vice President of HR
70

Chembio Diagnostics, Inc. Competitors